Cordis starts trial of new AAA stent
This article was originally published in Clinica
Executive Summary
A new stent called Incraft is being developed by Cordis as a treatment for abdominal aortic aneurysm (AAA). The Johnson & Johnson subsidiary has started an open-label, non-randomised trial called INNOVATION, which will enrol 25 AAA patients. The stent can be customised to the individual patient during the implantation procedure, and has an "ultra-low-profile delivery system". Incraft's delivery system profile is 13 French, whereas most endovascular aneurysm repair (EVAR) devices have a profile ranging from 18 to 24 French. This should broaden the patient population who can be treated with stents; many AAA patients, especially women, cannot undergo EVAR because current stents are too large to be placed in small or diseased access vessels. An estimated 27 million people worldwide have AAAs. Left untreated, all aneurysms will eventually rupture, and ruptured aneurysms are fatal in more than 80% of cases.
You may also be interested in...
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.